Hostname: page-component-8448b6f56d-t5pn6 Total loading time: 0 Render date: 2024-04-23T08:13:57.599Z Has data issue: false hasContentIssue false
  • English
  • Français

Venlafaxine and CYP2D6 in clinical practice: An observational study

Published online by Cambridge University Press:  16 April 2020

P. Zeppegno ,
R. Rolla ,
V. Dalo ,
F. Ressico ,
A. Parafioriti ,
P. Prosperini ,
G. Bellomo  and
E. Torre
P. Zeppegno
Affiliation:
Department of Clinical and Experimental Medicine, Institute of Psychiatry, University of Eastern Piedmont, Novara, Italy
R. Rolla
Affiliation:
Department of Medical Sciences, Molecular Diagnostics Laboratory, Clinical Chemistry Unit, University of Eastern Piedmont, Novara, Italy
V. Dalo
Affiliation:
Department of Clinical and Experimental Medicine, Institute of Psychiatry, University of Eastern Piedmont, Novara, Italy
F. Ressico
Affiliation:
Department of Clinical and Experimental Medicine, Institute of Psychiatry, University of Eastern Piedmont, Novara, Italy
A. Parafioriti
Affiliation:
Department of Clinical and Experimental Medicine, Institute of Psychiatry, University of Eastern Piedmont, Novara, Italy
P. Prosperini
Affiliation:
Department of Clinical and Experimental Medicine, Institute of Psychiatry, University of Eastern Piedmont, Novara, Italy
G. Bellomo
Affiliation:
Department of Medical Sciences, Molecular Diagnostics Laboratory, Clinical Chemistry Unit, University of Eastern Piedmont, Novara, Italy
E. Torre
Affiliation:
Department of Clinical and Experimental Medicine, Institute of Psychiatry, University of Eastern Piedmont, Novara, Italy

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Venlafaxine is a serotonin-norepinephrine inhibitor, mainly metabolized by CYP2D6 to its active metabolite ODV. Depending on CYP2D6 activity, patients may be identified as Poor, Intermediate, Extensive or Ultrarapid Metabolizers. There is some evidence that a PM phenotype is associated with poor tolerance more often than an EM; while a UM patient would only respond to a greater dose of Venlafaxine1.

Objectives

To evaluate the impact of CYP2D6 phenotype on the efficacy of Venlafaxine XR in depressed patients.

Methods

This observational study evaluated 27 Caucasian adult patients (F = 18, M = 9), satisfying DSM-IV criteria for Major Depressive, Bipolar Disorder or Personality Disorder receiving treatment with Venlafaxine 75–300 mg/die.

CYP2D6 alleles were evaluated with INFINITI CYP2D6 assay, which employs AutoGenomics proprietary film-based microarray technology.

Results

Most patients were identified as EMs, 4 as PMs, while only one was identified as UM. The only statistically significant difference between Extensive and Poor Metabolizers was, in contrast with current literature, the need of a greater mean dose of Venlafaxine in the second group (225 mg/die vs 159.38 mg/die, t student: p = 0.01).

Likewise, in contrast with literature, the UM patient was responsive to average doses of Venlafaxine.

On the contrary, we found no statistically significant differences as far as efficacy, adverse events or duration of treatment are concerned.

Conclusions

In our sample, CYP2D6 metabolizer status does not seem to affect treatment response nor adverse events related to Venlafaxine.

Type
P02-455
Information
European Psychiatry , Volume 26 , Issue S2: Abstracts of the 19th European Congress of Psychiatry , March 2011 , pp. 1051
Copyright
Copyright © European Psychiatric Association 2011
Submit a response

Comments

No Comments have been published for this article.